BioNTech SE ADR [BNTX] stock prices are up 2.76% to $109.0 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BNTX shares have gain 9.16% over the last week, with a monthly amount glided 18.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on January 16, 2026, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $142 for it. Previously, H.C. Wainwright reaffirmed its Buy rating on June 05, 2025, and elevated its price target to $145. On May 29, 2025, Goldman initiated with a Neutral rating and assigned a price target of $110 on the stock. Citigroup started tracking the stock assigning a Buy rating and suggested a price target of $145 on March 13, 2025. Truist initiated its recommendation with a Buy and recommended $172 as its price target on January 10, 2025. Wells Fargo started tracking with an Overweight rating for this stock on December 11, 2024, and assigned it a price target of $170. In a note dated December 02, 2024, BMO Capital Markets reiterated an Outperform rating on this stock.
The stock price of BioNTech SE ADR [BNTX] has been fluctuating between $81.20 and $126.77 over the past year. Currently, Wall Street analysts expect the stock to reach $144.2 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $109.0 at the most recent close of the market. An investor can expect a potential return of 32.29% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
The BioNTech SE ADR [NASDAQ:BNTX] reported sales of 3.53B for trailing twelve months, representing a surge of 29.80%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.3%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that BioNTech SE ADR [NASDAQ:BNTX]’s Current Ratio is 7.12. As well, the Quick Ratio is 7.02, while the Cash Ratio is 4.54. Considering the valuation of this stock, the price to sales ratio is 7.42, the price to book ratio is 1.21.
Transactions by insiders
Recent insider trading involved Tureci Ozlem, Officer, that happened on Nov 28 ’25 when 0.12 million shares were purchased. Officer, Medine GmbH completed a deal on Nov 13 ’25 to buy 1.11 million shares. Meanwhile, Director Jeggle Helmut Wolfgang bought 0.15 million shares on Nov 05 ’25.
